CAR T-cells for T-cell malignancies challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

Abstract : Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrated remarkable efficacy for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell malignancies appears more challenging due to the similarities between the therapeutic, normal and malignant T-cells. The obstacles include CAR T-cell fratricide, T-cell aplasia, and contamination of CAR T-cell products with malignant T-cells. Here, we review these challenges and propose solutions to overcome these limitations.
Document type :
Journal articles
Complete list of metadatas

Cited literature [1 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01903063
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, November 13, 2018 - 10:46:07 AM
Last modification on : Thursday, April 11, 2019 - 4:02:13 PM
Long-term archiving on : Thursday, February 14, 2019 - 1:33:13 PM

File

Houot_CAR T-cells for T-cell m...
Files produced by the author(s)

Identifiers

Citation

Marion Alcantara, Melania Tesio, Carl H June, Roch Houot. CAR T-cells for T-cell malignancies challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (11), pp.2307-2315. ⟨10.1038/s41375-018-0285-8⟩. ⟨hal-01903063⟩

Share

Metrics

Record views

143

Files downloads

155